Tolcapone Treatment of Pathological Gambling
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00927563|
Recruitment Status : Completed
First Posted : June 25, 2009
Results First Posted : March 6, 2014
Last Update Posted : March 6, 2014
|Condition or disease||Intervention/treatment||Phase|
|Pathological Gambling||Drug: Tolcapone||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Tolcapone Treatment of Pathological Gambling: An Open-Label Study|
|Study Start Date :||June 2009|
|Actual Primary Completion Date :||May 2012|
|Actual Study Completion Date :||July 2012|
pill, 100-300mg/day for 8 weeks
Other Name: Brand name: TASMAR
- Clinical Global Impression Scale (CGI) [ Time Frame: Visit 5 (final visit) ]The overall impression of the clinician of the severity of the subject. Scores between 1 and 7 with 1 not being ill at all and 7 being one of the worst cases seen. CGI is assessed at every visit (1-5), but only the final visit will be reported here.
- Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) [ Time Frame: Visit 5 (final visit) ]Scale used to measure severity of gambling. Scores could range from 0-40 with 0 being the least severe and 40 being the most severe. Here the total score was used. The PG-YBOCS was completed at every visit (1-5), but the final visit (visit 5) will be the only score reported.
- Gambling Symptom Assessment Scale (G-SAS) [ Time Frame: Visit 5 (final visit) ]Self report test of severity of gambling on a scale from 0-48 with 48 being the most severe. The G-SAS was performed at every visit (1-5), but only the final visit (visit 5) will be reported here as a final score.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00927563
|United States, Minnesota|
|Ambulatory Research Center|
|Minneapolis, Minnesota, United States, 55454|
|Principal Investigator:||Jon E Grant, MD, JD||University of Minnesota - Clinical and Translational Science Institute|